Erin Hertlein, PhD
College of Medicine
Res Asst Professor
Leukemia, Lymphocytic, Chronic, B-Cell, Cancer, Leukemia, Lymphoma, Lymphoma, Mantle-Cell, Leukemia, B-Cell, Leukemia, Hairy Cell
Dr. Hertlein has been extensively involved in NF-?B and other cancer relevant cell signaling pathways throughout my career. Her work has focused on the mechanism of several therapeutic agents in chronic lymphocytic leukemia (CLL). She is currently pursuing novel therapies which target Hsp90, EZH2, IDH proteins and other epigenetic pathways in lymphoid and myeloid diseases including diffuse large B cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Dr. Hertlein's focus includes studying the therapeutic mechanisms of these agents, including combination therapy and clinical application. She is also investigating how these epigenetic modifiers intersect with non-coding RNAs (miRs, lncRNAs) to mediate transcriptional regulation.